Skip to main content

Table 2 Cost savings for PCV13 vs. PCV7 pediatric vaccination in normal and pandemic influenza seasons

From: Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States

Influenza scenario IPD Hospitalized pneumonia Non-Hospitalized pneumonia Vaccination Total
Normal season $ 235 M $ 509 M $ 96 M ($ 367 M) $ 472 M
Pandemic similar to 2009–2010 H1N1 $ 358 M $ 812 M $ 213 M ($ 367 M) $ 1.02 B
  1. IPD, Invasive pneumococcal disease; M, Million; B, Billion.